AsiaIPEX is a one-stop-shop for players in the IP industry, facilitating IP trade and connection to the IP world. Whether you are a patent owner interested in selling your IP, or a manufacturer looking to buy technologies to upgrade your operation, you will find the portal a useful resource.

Anti-Igf-Ir Antibodies And Uses Thereof

Summary
The Subject Invention Provides Antibodies, Or Binding Fragments Thereof, That Specifically Bind To Human Igf-Ir. Also Provided Are Nucleic Acid Molecules Encoding The Antibodies And Binding Fragments Of The Subject Invention And Vectors And Host Cells Containing These Nucleic Acid Molecules. The Disclosure Also Provides Methods Of Inhibiting Cancer Cell Growth And Metastasis In A Mammal Using The Antibodies Described Herein, As Well As Compositions Containing The Antibodies, Nucleic Acid Molecules Encoding The Antibodies, And Host Cells And Vectors Comprising The Nucleic Acid Molecules. The Disclosure Also Features The Use Of The Polypeptides To Detect The Presence Of Igf-Ir In A Mammal, And Epitopes That Can Be Used As Cancer Vaccine Immunogens.
Supplementary Information
Patent Number: US8444982B2
Application Number: US2010955627A
Inventor: Zhang, Mei-Yun
Priority Date: 4 Dec 2009
Priority Number: US8444982B2
Application Date: 29 Nov 2010
Publication Date: 21 May 2013
IPC Current: A61K0039395 | C07K001600
US Class: 4241431 | 5303871 | 5303873 | 5303879 | 5303881 | 53038822
Assignee Applicant: The University of Hong Kong
Title: Anti-IGF-IR antibodies and uses thereof
Usefulness: Anti-IGF-IR antibodies and uses thereof
Summary: For treating a tumor or cancer in subject such as human, where the cancer is prostate cancer, breast cancer, liver cancer, or colon cancer (claimed).
Novelty: New isolated antibody that specifically binds to human insulin-like growth factor I receptor, useful for treating tumor or cancer e.g. prostate, breast or liver
Industry
Chemical/Material
Sub Category
Chemical/Material Application
Application No.
US2010955627A
Country/Region
Hong Kong

For more information, please click Here
Mobile Device